June 12, 2019 / 6:52 AM / 4 days ago

BRIEF-Novo Nordisk: PIONEER 6 Trial Achieved Its Primary Endpoint

June 12 (Reuters) - Novo Nordisk A/S:

* SAID ON TUESDAY THE PIONEER 6 TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING NON-INFERIORITY OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH ORAL SEMAGLUTIDE COMPARED WITH PLACEBO, BOTH IN ADDITION TO STANDARD OF CARE

* NUMBER OF NON-FATAL MYOCARDIAL INFARCTIONS WITH ORAL SEMAGLUTIDE WAS NOT SIGNIFICANTLY DIFFERENT THAN PLACEBO

* AMONG THE SECONDARY ENDPOINTS, THE NUMBER OF ALL-CAUSE DEATHS WAS SIGNIFICANTLY LOWER IN PEOPLE TREATED WITH ORAL SEMAGLUTIDE COMPARED WITH PLACEBO

* THE PIONEER 6 TRIAL DEMONSTRATES THAT ORAL SEMAGLUTIDE DOES NOT INCREASE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS WHILE PROVIDING FURTHER EVIDENCE FOR THE OVERALL CARDIOVASCULAR PROFILE OF SEMAGLUTIDE

* SAFETY PROFILE OF ORAL SEMAGLUTIDE WAS CONSISTENT WITH THAT OF THE GLP-1 RECEPTOR AGONIST CLASS AND SIMILAR TO THOSE SEEN WITH SUBCUTANEOUS SEMAGLUTIDE

Source text: bit.ly/2R8fHW0

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below